Classical concept of mammalian tachykinin peptide
In 1931, von Euler and Gaddum purified the first substance designated as preparation P or powder P from the brain and intestine of rabbits and found that it had an effect on blood pressure and contraction of intestinal tissue [1] . The pure form of this substance, substance P (SP), was not isolated for the next 40 years. A peptide named sialogen was isolated in 1967 from the bovine and rat hypothalamus [2] . In 1970, by comparing their biological activity and chemical properties, it was realized that sialogen and SP are the same [3] . Thereafter, the chemical structure of SP was determined as an amidated undecapeptide [4] and SP was chemically synthesized (Table 1 ) [5] . Over the next 10 years, SP was believed to be the only mammalian tachykinin peptide. In 1983, two further members of the mammalian tachykinin family were isolated from the porcine spinal cord and were designated as neurokinin A (NKA, substance K, neuromedin L) (Table 1 ) [6, 7] and neurokinin B (NKB, neuromedin K) (Table 1 ) [8, 9] . On the other hand, based on a cloning study for the precursor of mammalian tachykinin, it was verified that the preprotachykinin A (PPT-A, TAC1) [10, 11] encodes SP and NKA, while NKB is encoded in preprotachykinin B (PPT-B, TAC3) [12] . In 1989, receptors of each of these three mammalian tachykinins were cloned and designated as neurokinin 1 (NK1), neurokinin 2 (NK2) and neurokinin 3 (NK3) receptors [13] [14] [15] [16] [17] [18] [19] . Thus, until recently, it had been believed that mammalian tachykinin peptides consist of three members, SP, NKA and NKB, which are short peptides 10-11 amino acids in length. Furthermore, these peptides share the same conserved hydrophobic carboxyl-terminal (C-terminal) region, Phe-X-Gly-Leu-Met-NH 2 , which is central to the activation of each of three mammalian tachykinin receptors. In contrast, in the amino-terminal (N-terminal) region, they possess divergent and hydrophilic regions believed to convey receptor specificity, whereby SP shows the highest affinity for NK1, NKA for NK2 and NKB for NK3 receptor [17] [18] [19] . Namely, it seems likely that NK1, NK2 and NK3 receptors are receptors of SP, NKA and NKB, respectively. In 2000, this consensus had to be changed after the discovery of a fourth mammalian tachykinin in mice [20] .
2. Structure and distribution of hemokinin-1
Identification of PPT-C (TAC4) in mammals
A new cDNA molecule was identified from an mRNA differential display for isolating new growth and differentiation factors involved in mouse B cell development [20] . The 
cloned cDNA had an open reading frame encoding a peptide of 128 amino acids with a 15 amino acid region, Lys-ArgSer-Arg-Thr-Arg-Gln-Phe-Tyr-Gly-Leu-Met-Gly-LysArg, that is similar to tachykinin peptides, since this region possesses all the sequence information necessary for the liberation and maturation of a tachykinin peptide. Specifically, the basic Lys-Arg doublets at each end are typical cleavage sites, and the Gly residue adjacent to the COOHterminal Met residue provides the NH 2 group for COOHterminal amidation of the mature tachykinin peptide. The pentapeptide sequence Phe-Tyr-Gly-Leu-Met matches the tachykinin signature motif Phe-X-Gly-Leu-Met. Thus, it was suggested that the cDNA molecule is a new mouse preprotachykinin gene, mPPT-C (mTAC4), and the putative tachykinin peptide encoded by mTAC4 was named hemokinin-1 (HK-1), because this gene was restrictedly expressed in hematopoietic cells, and the structure of HK-1 was proposed as Arg-Ser-Arg-Thr-Arg-Gln-Phe-Tyr-Gly-Leu-Met-NH 2 (Table 1 ) [20] . Subsequently, the rat TAC4 encoding a precursor protein of 170 amino acids was identified. This precursor protein encoding a rat HK-1 peptide (rHK-1) displayed 76% identity to that of the mouse (mHK-1) and the amino acid sequence of rHK-1 was identical to that of mHK-1, so it was named rat/mouse hemokinin (r/mHK-1) [21] . Similarly, cDNA encoding a precursor protein of 98 amino acids was identified from human hypothalamic and thymus DNA and was designated human preprotachykinin C (hPPT-C, hTAC4)) [21] . The putative peptide encoded by hTAC4 was also homologous to that of mTAC4; however, unlike the mTAC4 gene in which dibasic cleavage sites flank the predicted HK-1 peptide, the putative peptide encoded by hTAC4 contained two potential monobasic cleavage sites (Lys) in the N-terminal region, Lys-Thr-Gly-Lys-Ala-Ser-Gln-PhePhe-Gly-Leu-Met-Gly-Lys-Arg. As a result, the putative peptide of human HK-1 (hHK-1) has the potential to generate the full-length Thr-Gly-Lys-Ala-Ser-Gln-Phe-Phe-GlyLeu-Met-NH 2 (Table 1) , as well as a truncated version, AlaSer-Gln-Phe-Phe-Gly-Leu-Met-NH 2 , of predicted human HK-1 [21] .
Tissue distribution of TAC4
The mTAC4 gene was restrictedly expressed in bone marrow, while there was little expression of TAC4 mRNA in the mouse brain and spleen [20] . Detailed examination of the expression pattern of mTAC4 and hTAC4 revealed the differential expression of these mRNAs in various tissues. For example, moderate to strong signals of mTAC4 were detected in the brain, spleen, stomach, and skin, while stronger expression of hTAC4 was seen in the heart, muscle, skin, and thyroid.
Thus, TAC4 appears to be expressed in certain peripheral tissues and in the brain of both humans and rodents [21] . By contrast, comparison of mTAC4 and mTAC1 expression showed tissue-dependent differences. Indeed, the expression of mTAC4 was found in the majority of peripheral tissues, while mTAC1 had more limited distribution in the central nervous system (CNS). These findings suggest that HK-1 may be a functional agonist at NK1R in the CNS as well as in peripheral tissues [22] , and strong expression of TAC4 in the skin suggests that HK-1 may play a crucial role in inflammation or somatosensory perception, such as touch, pain or itch.
It is known that the expression level of TAC1 is modified in pathophysiological conditions such as nerve injury; however, there was a little information about changes in the expression level of TAC4. Recently, the increased level of TAC4 mRNA was demonstrated in the dorsal horn after chronic constrictive injury (CCI) of the rat sciatic nerve, and the increased expression of TAC4 mRNA after CCI was blocked by treatment with an inhibitor of microglial activation. This indicates that the increased expression of TAC4 mRNA is involved, at least in part, in the activation of microglial cells after nerve injury [23] . Furthermore, the expression of TAC4 mRNA was upregulated in the microglia upon their activation by lipopolysaccharide, whereas TAC1 mRNA expression was downregulated, suggesting that HK-1, rather than SP, plays crucial roles in pathological conditions associated with microglial activation [24] .
Pharmacological characteristics of HK-1
The high degree of homology between amino acid sequences of SP and r/mHK-1 suggests that r/mHK-1 peptide may interact with the SP-preferred receptor, NK1 receptor. Competition binding experiments of r/mHK-1 in cells transfected with NK1 receptor showed identical binding affinity to that of SP, and calcium influx in cells expressing NK1 receptor following r/mHK-1 administration was equipotent to SP, suggesting that r/mHK-1 may be a full agonist at NK1 receptor [25] . Subsequent study demonstrated that r/mHK-1 and SP bound to the human NK1 receptor with similar affinity, while r/mHK-1 had reduced affinity for the human NK2 receptor and NK3 receptor relative to the NK1 receptor [21, 22] . In addition, calcium mobilization by hHK-1 and r/mHK-1 showed potency equal to SP on the human NK1 receptor expressed in CHO cells [21] , and SP and r/mHK-1 displayed higher affinity at the human NK1 receptor expressed in CHO cells [22, 26] . Similarly, the effect of bath application of SP and r/mHK-1 on the rabbit jugular vein expressing NK1 receptor was examined, and similar kinetics of action of SP and HK-1 was demonstrated [27] . These results indicate that r/mHK-1 is an agonist at NK1 receptor, and both SP and r/ mHK-1 competitively bind to the NK1 receptor; however, these data could not always rule out the possible existence of an HK-1-preferring receptor [20, 28] .
Pharmacological effects of HK-1
Since the discovery of r/mHK-1, many studies have focused on its biological actions, including immunological regulation and inflammation [20, [29] [30] [31] [32] [33] , female reproductive function [34] [35] [36] [37] and cardiovascular activities [26, [38] [39] [40] . As space is limited for a full explanation of these fields and data from the pain field are relatively abundant, the main subject of this review will be the biological role of HK-1 in nociceptive processing.
Effects of intracerebroventricular administration of HK-1
First, it was demonstrated that injection of r/mHK-1 and SP into the third ventricle produced a dose-dependently increase in foot-tapping in gerbils and scratching in mice and these HK-1-induced behaviors were blocked by a selective NK1 receptor antagonist [22] , indicating that r/mHK-1 is involved in the induction of these behavioral responses through the NK1 receptor. Subsequently, to observe the effects of r/mHK-1 on nociceptive processing at the supraspinal level in mice, different concentrations of r/m HK-1 were administered into the third ventricle and the effect of r/ mHK-1 was evaluated by the warm-water tail-immersion test. Intracerebroventricular (i.c.v.) administration of r/m HK-1 induced the analgesic effect in nanomole concentration, while picomolar doses produced hyperalgesia. These effects were attenuated by co-injection with a selective NK1 receptor antagonist, suggesting that r/mHK-1 may play a crucial role in nociceptive processing at the supraspinal level in mice and both conflicting effects of r/mHK-1 may be elicited through the activation of NK1 receptor [41] . Furthermore, the antinociceptive effect induced by r/mHK-1 administration was attenuated by pretreatment with naloxone, an opioid receptor antagonist [41] , indicating that there is a functional interaction between supraspinal HK-1 and opioid systems. Indeed, i.c.v. administration of r/mHK-1 significantly potentiated the antinociceptive effects of morphine or pethidine, an opioid receptor agonist, indicating that the potential analgesic response induced by i.c.v. administration of r/m HK-1 is mediated by opioid-responsive neurons [42, 43] . On the other hand, the effects of hHK-1 and hHK-1 (4-11) were investigated by the tail immersion test following i.c.v. administration at the supraspinal level in mice. The antinociceptive effect produced by i.c.v. administration of hHK-1 was significantly antagonized by an NK1 receptor antagonist, indicating that the analgesic effect induced by i.c.v. administration of hHK-1 is mediated through the activation of NK1 receptor. Similarly, naloxone blocked the analgesic effect of hHK-1, suggesting that this effect is related to opioidergic neurons. On the other hand, i.c.v. administration of hHK-1 (4-11) also produced an antinociceptive effect; however, this effect was not attenuated by administration of an NK1 receptor antagonist or naloxone, suggesting that the mechanisms underlying the antinociceptive effect induced by hHK-1 and hHK-1 (4-11) may be different [44] .
In summary, it seems likely that i.c.v. administration of HK-1 elicits antinociceptive effects through the NK1 receptor and this effect is derived from activation of the opioid system.
Effects of intrathecal administration of HK-1
It is well known that intrathecal administration of SP induces scratching behavior and thermal hyperalgesia [45, 46] . Scratching behavior was also induced by intrathecal administration of r/mHK-1 [47, 48] , and HK-1-induced scratching behavior was attenuated by pretreatment with an NK1 receptor antagonist [47] , whereas SP-induced scratching behavior was inhibited by pretreatment with EKC/D (using the common carboxyl-terminal duodecapeptide in endokinin C and endokinin D), but failed to attenuate HK-1-induced scratching behavior [49] . Similarly, intrathecal administration of r/ mHK-1 produced scratching, biting and licking behaviors. These behaviors induced by low-dose HK-1 were inhibited by CP-99,994, a non-peptidic NK1 receptor antagonist, whereas sendide, a peptidic NK1 receptor antagonist, failed to reduce the behavior responses, although SP-induced behaviors were suppressed by both CP-99,994 and sendide [50] . These findings indicate that the mechanism underlying the induction of behaviors by r/mHK-1 is partially different from that of SP.
Repeated intrathecal administration of SP produced desensitization in SP-induced behavior such as scratching, biting and thermal hyperalgesia [51] [52] [53] [54] . Similarly induction of desensitization in scratching behavior was also recognized after repeated administration of r/mHK-1 [48, 49, 55] . Indeed, marked desensitization of scratching behavior was recognized when r/mHK-1 was administered twice. Furthermore, the first administration of SP produced clear crossdesensitization to r/mHK-1, while the first administration of r/mHK-1 demonstrated weak cross-desensitization to SP [48] . Induction of desensitization by repeated administration of r/mHK-1 was attenuated by pretreatment with an inhibitor of protein kinase A (PKA), protein kinase C (PKC) or mitogen-activated protein kinase (MEK), while there was little effect of an inhibitor of calcium/calmodulin kinase II (CaMKII) on r/mHK-1-induced desensitization, although pretreatment with these four kinase inhibitors inhibited the induction of desensitization by SP [55] . Since it is believed that desensitization is induced by binding of peptide to its receptor, the difference in the mode of induction of crossdesensitization between r/mHK-1 and SP and in kinases involved in the induction of desensitization suggests that the receptor of r/mHK-1, HK-1-preferring receptor, may be different from the SP-preferring receptor, NK1 receptor.
Another notable difference between the effects of r/ mHK-1 and SP is the scarcely induced thermal hyperalgesia by intrathecal administration of r/mHK-1, but not SP [47] . This issue has been partially resolved by synthesizing chimera peptides between r/mHK-1 and SP. When two chimera peptides between the N-terminal region of SP and the C-terminal region of r/mHK-1, and vice versa, SP (1-5)/HK-1 and HK (1-5)/SP (Table 1) , were intrathecally administered, SP (1-5)/ HK-1 induced thermal hyperalgesia whereas HK-1 (1-5)/SP had hardly any effect; furthermore, thermal hyperalgesia was induced by only C-terminal fragments of r/mHK-1 and SP, indicating that the N-terminal region of r/mHK-1 is involved in the non-induction of thermal hyperalgesia. Both SP (1-2)/ HK-1 and HK-1 (1-4)/SP induced thermal hyperalgesia whereas r/mHK-1 and HK-1 (1-5)/SP had hardly any effect, indicating that Ser at the 2nd position and Arg at the 5th position of r/mHK-1 may be involved in the non-induction of thermal hyperalgesia. Furthermore, HK-1 (1-2, 4-5)/SP, but not HK-1 (1-2,5)/SP and HK-1 (1-3,5)/SP, hardly induced thermal hyperalgesia, indicating that three amino acids, Ser, Thr and Arg at the 2nd, 4th and 5th position of r/mHK-1, respectively, regulate the induction of thermal hyperalgesia by r/mHK-1 [56] .
There is a functional relationship between r/mHK-1 and ion channels. Three transient receptor potential (TRP) channels, TRPV1, TRPA1 and TRPM8, and r/mHK-1, are similarly localized in the spinal dorsal horn and dorsal root ganglion [22, [57] [58] [59] [60] [61] [62] [63] [64] [65] . Thus, the effects of pretreatment with HK-1 on the induction of scratching behavior by TRP channel agonists were examined. Pretreatment with HK-1 enhanced the induction of scratching behavior by resiniferatoxin, a TRPV1 agonist, whereas scratching behavior induced by menthol, a TRPM8 agonist, was suppressed by pretreatment with HK-1.
On the other hand, there was little effect of pretreatment with HK-1 on the induction of scratching behavior by cinnamaldehyde, a TRPA1 agonist. Taken together, these results indicate that HK-1 differentially modulates the response of TRP channels [66] .
Structure and distribution of endokinins

Structure of hTAC4
A corresponding human TAC4 homologue to mouse and rat TAC4 was isolated and an HK-1-like decapeptide, Gly-LysAla-Ser-Gln-Phe-Phe-Gly-Leu-Met-NH 2 , with the tachykinin signature motif was predicted to be encoded on this precursor [21, 67] . This peptide does not share complete homology with mouse or rat HK-1. The human TAC4 proposed by Kurtz et al. [21] is encoded only on two exons equivalent to the first two coding exons of mice and rats. On the other hand, Page et al. [67] identified cDNA from the human spleen that rendered a much longer 113-amino acid precursor protein predicted to be encoded on five exons, indicating that there are three additional downstream exons in humans. Furthermore, this human TAC4 is spliced into four alternatively splice variants, a, b, g and d and four different peptides are predicted, classified as endokinin A (EKA), endokinin B (EKA), endokinin C (EKC) and endokinin D (EKD) ( Table 1) . EKA and EKB are encoded only aTAC4 and all four transcripts, respectively, and EKC and EKD are encoded by aTAC4 and bTAC4, respectively [67] .
EKA consists of 47 amino acids, while EKB is a 41 amino acid truncated from of EKA with deletion of six amino acids. EKA and EKB are N-terminal elongated forms of hHK-1, ThrGly-Lys-Ala-Ser-Gln-Phe-Phe-Gly-Leu-Met-NH 2 . EKC and EKD consist of 14 amino acids, and only two amino acids at the N-terminal are inconsistent between these two peptides. EKA and EKB share the C-terminal tachykinin signature motif, while EKC and EKD possess a different C-terminal sequence. An exception to their tachykinin signature motif in EKC and EKD is a transition from the C-terminal methionine to a leucine (Table 1) [28, [67] [68] [69] .
Distribution of hTAC4
To account for the extra level of complexity introduced by the different splice variants, Page et al. [67] examined this expression by designing specific PCR primers to overlap each unique exon junction and showed that a and bTAC4 have very restricted expression patterns. Indeed, aTAC4 was found only in the adrenal gland and fetal liver, and bTAC4 was detected in the heart, liver, bone marrow, prostate, adrenal gland and testis. In contrast, g and dTAC4 were ubiquitously expressed in human tissues with the most prolific expression in the adrenal gland and placenta. There was a low expression of TAC4 in the brain [28, [67] [68] [69] .
Pharmacological effects of endokinins
Intrathecal administration of EKA/B (the common C-terminal decapeptide in EKA and EKB, Table 1 ) induced scratching behavior and thermal hyperalgesia. Indeed, 10 À3 M (10 nmol/rat) of EKA/B produced scratching behavior and 10 À7 -10 À4 M (1 pmol-1 nmol/rat) induced thermal hyperalgesia, and their effects were attenuated by pretreatment with NK1R antagonists [70] . Also, when EKA/B was intrathecally administered twice with an interval of 15 min, marked desensitization of scratching behavior was induced. Furthermore, the first administration of EKA/B or SP produced clear cross-desensitization to SP or EKA/B [48] . On the other hand, i.c.v. administration of EKA/B (10, 30, 100 pmol/mouse) and EKA/B (1, 3, 12, 20 nmol/mouse) induced hyperalgesic and analgesic effects, respectively [71, 72] . These effects of EKA/ B were attenuated by treatment with SR140333B, an antagonist of NK1 receptor, indicating that the binding of EKA/B to the NK1 receptor elicited these effects.
Intrathecal or i.c.v. administration of EKC/D (the common C-terminal duodecapeptide in EKC and EKD, Table 1 ) elicited a different effect from EKA/B. Intrathecal administration of EKC/D alone did not evoke the scratching behavior and thermal hyperalgesia that were induced by EKA/B administration [70] , although i.c.v. administration of EKC/D (1, 3, 12 , 20 nmol/mouse) also dose-dependently induced analgesic effects [71] . However, pretreatment with EKC/D prevented the induction of scratching behavior and thermal hyperalgesia by intrathecal administration of EKA/B and SP, and c-Fos expression in laminae I/II and V/VI of the spinal cord by noxious thermal stimulation [49] . Furthermore, subcutaneous injection of EKC/D reduced an increase in paw volume following carrageenan-induced inflammation and the reduced withdrawal latency evoked by inflammation was also attenuated by EKC/D administration [73] . Similarly, the hyperalgesic effect induced by EKA/B was attenuated by EKC/D [71] .
A marked difference between EKC/D and SP or EKA/B is the presence of leucine instead of methionine at the carboxyl terminal of EKC/D (Table 1) . Thus, to clarify the effect of leucine at the carboxyl terminal of EKC/D, [Met 12 ]-EKC/D (Table 1) , in which only leucine at the carboxyl terminal of EKC/D was replaced with methionine, was intrathecally administered, and the effect of pretreatment with this peptide was evaluated. This peptide did not exhibit an inhibitory effect on SP-induced scratching behavior or thermal hyperalgesia, but conversely caused thermal hyperalgesia [49] . In addition, pretreatment with [Leu 11 ]-SP and [Leu 10 ]-EKA/B (Table 1) , in which methionine at the carboxyl terminal of SP or EKA/B was replaced by leucine, attenuated SP-induced scratching behavior and thermal hyperalgesia [74] . Based on these findings, it seems likely that leucine at the carboxyl terminal of EKC/D has a crucial role in eliciting inhibitory effects.
There is a structural similarity between EKC/D and some known SP-derived NK1 receptor antagonists such as Spantide I [75] and Antagonist D [76] , since they have leucine at the carboxyl terminus of these peptides. In addition, Spantide I and Antagonist D have a D-type amino acid, D-tryptophan (DTrp), at the seventh and ninth positions of SP. Since the peptide bonds of Gln6-Phe7, Phe7-Phe8 and Gly9-Leu10 in SP are hydrolyzed by endopeptidase-24.11 [77] , it is reasonable that the replacement of Phe7 and Gly9 in SP by D-Trp renders resistance to hydrolysis by this enzyme and produces metabolically stable SP-derived antagonists; however, the pharmacological effect of EKC/D-derived peptides with D-Trp was different from that of SP-derived peptides. Indeed, the effect of pretreatment with these peptides on SP-induced scratching and thermal hyperalgesia, formalininduced flinching and carrageenan-induced inflammation was dependent on the number of D 
Perspective
One subject that remains to be resolved is whether the HK-1-preferred receptor is identical to the NK1 receptor. Treatment with NK1 receptor antagonists attenuated behavioral responses induced by HK-1 as well as SP, indicating that HK-1 and SP elicit the effect through the NK1 receptor. On the other hand, pretreatment with EKC/D inhibited SP-induced scratching behavior while there was little effect on HK-1-induced scratching, indicating that EKC/D is a specific antagonist of the NK1 receptor, but not the HK-1-preferred receptor. In addition, there was a difference in a mode of induction of cross-desensitization and thermal hyperalgesia between r/mHK-1 and SP and in kinases involved in the induction of desensitization by HK-1 and SP. Taken together, a series of evidence suggests that the NK1 receptor may be different from the HK-1-preferred receptor. Discovery of specific antagonists against the HK-1-preferred receptor and identification of the HK-1-preferred receptor gene will provide a clue to clarify these unsolved issues.
Information on the distribution of TAC4 mRNA has been accumulated for various tissues, and the expression of TAC4 mRNA is evident in both peripheral tissues and the nervous system. The peripheral tissue and brain consist of various cell types in which each cell has specific functions; however, there is no information about the expression of TAC4 mRNA in each cell, since data on the expression of TAC4 mRNA are derived from blotting analyses. Development of a specific antibody against HK-1 is essential for determining the expression of HK-1 by immunohistochemistry in each cell, and application of in situ hybridization can clarify the localization of each cell expressing TAC4 mRNA in each tissue or the central nervous system. These data are useful for elucidating the function of HK-1 in each cell of various tissues.
Physiological functions of HK-1 in the spinal level or peripheral tissue remain to be elucidated, although the abundant expression of TAC4 mRNA in peripheral tissues and induction of scratching behavior following intrathecal administration of HK-1 have been identified. Scratching is a pain-related behavior since scratching behavior is induced by SP, which is known as a neurotransmitter in pain processing; however, the itch sensation also induces scratching behavior and pain induces wiping behavior [79] . Thus, analysis of behavior responses, such as scratching and wiping, after administration of HK-1 into peripheral tissues may be useful for clarifying the role of HK-1 in peripheral tissues.
Finally, most accumulated data are derived from the spinal or supraspinal level whereas there is little data on the function of HK-1 or endokinins in the trigeminal system. Thus, it is interesting to examine the role of HK-1 in the orofacial region while comparing with the effect of HK-1 in peripheral tissue at the spinal level.
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